Navigation Links
Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
Date:9/5/2007

's hospital, an investigator at the TIMI Study group and lead author of the study.

These data represent the first clinical report of the effect of ranolazine to reduce the incidence of cardiac arrhythmias and support the findings of many prior preclinical studies which have suggested that ranolazine has potential anti-arrhythmic properties due to its action as an inhibitor of the late sodium current.

In accordance with a special protocol assessment agreement between the U.S. Food and Drug Administration (FDA) and CV Therapeutics, the Company believes that data from the MERLIN TIMI-36 study could support expansion of the existing Ranexa indication to first line angina, and plans to submit a supplemental new drug application to the FDA in fall 2007. CV Therapeutics plans to ask the FDA to modify the existing product labeling for Ranexa by reducing cautionary language and expanding the indication to include first- line angina.

Ranexa is currently indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

Study Design

MERLIN TIMI-36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) was a multi-national, double-blind, randomized, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of Ranexa during acute and long-term treatment in 6,560 patients (3,279 received ranolazine, 3,281 received placebo) with non-ST elevation ACS treated with standard therapy.

Within 48 hours of the onset of angina due to ACS, eligible hospitalized patients were enrolled in the study and randomized to receive intravenous Ranexa or placebo, followed by long-term outpatient treatment with Ranexa extended-release tablets or placebo. All patients also received standard therapy during both hospital-based and outpatient treatm
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Third coast of biotechnology makes strong showing at VC conference
2. Reforming FDA: Focus on safety, let market judge efficacy
3. Funds will support public safety communications interoperabilty
4. High interest forces delay in food safety symposium
5. Human factors and IT: Designing for patient safety
6. UW Medical Foundation CEO shares his vision on the state of health care and patient safety
7. UW symposium to explore impact of IT on improving quality, safety and cost of healthcare
8. Thompson receives leadership award for technology solutions for patient safety
9. Effects of Thermal Cycler Well-To-Well Temperature Uniformity on PCR Results
10. Measuring Gene Silencing Effects by RT-PCR Without RNA Isolation
11. Confirming RNAi Effects Is Now Easier Than Ever
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Texas (PRWEB) September 23, 2014 ... the current state of the Phenolic Resin industry ... overview of the industry, including definitions, applications and ... domestic market analysis are provided with a focus ... the market. A comparison between the international and ...
(Date:9/23/2014)... 2014 Research and Markets  has ... for Research and IVD Applications (Mass Spectrometry, Chromatography, ... their offering. This report defines ... in their research use and in IVD.  Proteomics ... of the structure and function of proteins. This ...
(Date:9/23/2014)... September 23, 2014 Proove Biosciences ... presented industry leading research and data on the association ... the American Academy of Pain Management’ s ... Phoenix, Arizona at the , Proove Biosciences ... gender and genetic predisposition to opioid misuse risk in ...
(Date:9/23/2014)... , Sept. 23, 2014  Age Defying Dermatology ... Noodleman , has become one of the first clinics ... only "picoseconds" aesthetic laser for tattoo removal. The treatment ... better results. "For years, tattoo removal has been a ... Dr. Noodleman. "This is an opportunity to erase tattoo ...
Breaking Biology Technology:Phenolic Resin Industry (International, China) Development Policy and Plan Now Available at ReportsnReports.com 2Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 2Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 3Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays, Other Technologies) 4Proove Biosciences Will Be Exhibiting I.M.P.L.O.R.E Study at the American Academy of Pain Management 25th Annual Meeting 2Proove Biosciences Will Be Exhibiting I.M.P.L.O.R.E Study at the American Academy of Pain Management 25th Annual Meeting 3Age Defy Now Offers World's Most Advanced Technology for Tattoo Removal 2
... DURHAM, N.C. -- Duke University and United States Army ... and diaper rash preventative can be made to produce ... Duke adjunct physics professor Henry Everitt, chemistry professor Jie ... that adding sulfur to ultra-fine powders of commonplace zinc ...
... 17 St. Joseph,s Hospital and Medical Center, Phoenix, today ... Clinical InfoNET videoconferencing system to connect specialist ... This program will include the Barrow Neurological Institute, as ... , With the objective of ...
... Calif., Dec. 17 Senetek PLC,(OTC Bulletin Board: SNKTY), ... that target the science of healthy aging, today,announced that ... proposed at the Annual General Meeting of Shareholders held ... "We are pleased with the results of the ...
Cached Biology Technology:Duke researchers coax bright white light from unexpected source 2Duke researchers coax bright white light from unexpected source 3St. Joseph's Hospital and Medical Center to Utilize Clinical InfoNET System for Physicians 2St. Joseph's Hospital and Medical Center to Utilize Clinical InfoNET System for Physicians 3Senetek PLC Announces 2008 Annual General Meeting Voting Results 2
(Date:9/23/2014)... SANTA CLARA, California , 23 de ... anuncia el lanzamiento del Sistema 1290 Infinity ... serie 1200 de Infinity en su portafolio ... los técnicos, científicos y directores de laboratorio ... calidad analítica excepcional, facilidad de uso y ...
(Date:9/23/2014)... immediate welfare consequences of removing infant chimpanzees from their ... long-term impacts of this type of early life experience. ... observed 60 chimpanzees and concluded that those who were ... by humans as pets or performers are likely to ... multi-institutional research project, published today in the open-access journal ...
(Date:9/22/2014)... Chicago have shown that after a long stay in ... pathogenic microbe species remain behind in patients, intestines. The ... can become deadly when provoked by conditions that mimic ... published in mBio , the online open-access journal ... better monitoring and treatment of ICU patients who can ...
Breaking Biology News(10 mins):Agilent Technologies anuncia el lanzamiento del Sistema 1290 Infinity II LC 2Agilent Technologies anuncia el lanzamiento del Sistema 1290 Infinity II LC 3Chimpanzees raised as pets or performers suffer long-term effects on their behavior 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3
... (FiO), the 91st Annual Meeting of the Optical Society ... San Jose, Calif., alongside Laser Science XXIII, the annual ... Science. Reporters interested in obtaining a badge to ... cmorri@osa.org . FiO RESEARCH HIGHLIGHTS ...
... Makes Tuna That Tastes Good, But These Bluefin Are ... bluefin tuna caught in the Gulf of Maine has ... University of New Hampshire have found by analyzing detailed ... Fishermans Co-op. The findings, published this week in Fishery ...
... the social habits of living cells an innovation ... help fight diseases such as cancer and diabetes. ... six countries, The Manchester Centre for Integrative Systems Biology ... research into an emerging field of science and engineering ...
Cached Biology News:Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 2Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 3Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 4Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 5Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 6Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 7Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 8Condition of bluefin tuna in gulf of maine is declining 2Condition of bluefin tuna in gulf of maine is declining 3Social habits of cells may hold key to fighting diseases 2
Request Info...
... The Cetac Ultrasonic Nebulizers are available in two ... difference between these two models is that the ... to create a drier aerosol for improved detection ... detection limits for a range of elements by ...
... inhibition of RNase A-type ribonucleases Product Description: ... nonhuman origin that binds noncovalently and inactivates ... B, and C). It does not interfere ... or CL3. QIAGEN RNase Inhibitor inhibits greater ...
... is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
Biology Products: